News
INO
9.86
-2.95%
-0.30
Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation
Inovio Pharmaceuticals, Inc. Specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent respiratory papillomatosis. Inovio is preparing for a BLA in 2024 and has the potential for accelerated FDA approval and a 2025 launch. However, the company faces financial and valuation concerns, with a high valuation multiple and a low cash runway.
Seeking Alpha · 1d ago
Inovio Pharmaceuticals: The Dilution Continues
Inovio Pharmaceuticals, Inc. Has diluted its stock at a 30% discount. The company's latest pipeline candidate, INO-3107, is expected to submit a BLA in the second half of 2024. The potential market size for the drug is $770 million. The stock might be worth a speculative long position at $7.50 or below.
Seeking Alpha · 2d ago
Weekly Report: what happened at INO last week (0415-0419)?
Weekly Report · 3d ago
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Sk Skillsoft Corp. Shares dipped 26.7% to $6.74 on Tuesday. The company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. WiSA Technologies, Inc. Shares jumped 85% after the company announced a licensing agreement with an HDTV/PTV brand.
Benzinga · 04/16 18:17
Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?
Inovio Pharmaceuticals Inc. Announced the pricing of a public offering of 2,536,258 shares of its common stock. The company anticipates gross proceeds of approximately $36 million. Inovio is a biotechnology company focused on developing and commercializing DNA medicines.
Benzinga · 04/16 13:29
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Macatawa Bank Corporation rose sharply in today’s pre-market trading after the company announced a merger agreement with Wintrust Financial Corporation. Dynatronics Corporation shares rose 69.8% to $0.6301 in pre- market trading. Groupon, Inc. Shares fell 8.9% in today's trading.
Benzinga · 04/16 12:14
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Dynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap rose to $3.3 million. Inovio Pharmaceuticals shares fell 24.3% during the session. Akanda shares increased by 23.0% and BioRestorative Therapies shares moved upwards.
Benzinga · 04/16 12:07
Inovio falls after pricing stock offering
Inovio Pharmaceuticals, Inc. Lost 21% premarket Tuesday. DNA medicine developer priced an underwritten offering of its common stock below its currently traded price. Plymouth Meeting, a Pennsylvania-based biotech, intends to raise $36M in gross proceeds from the offering.
Seeking Alpha · 04/16 11:48
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Dynatronics stock is rocketing more than 97% alongside heavy pre-market trading on Tuesday morning. Dragonfly Energy shares are soaring 55% after releasing its Q4 2023 earnings report. The biggest pre- market stock movers on Tuesday include Dynatronics and an acquisition agreement.
Investorplace · 04/16 11:35
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Shares of Live Nation Entertainment, Inc. Fell sharply in today’s pre-market trading. The Justice Department is expected to file an antitrust lawsuit against the company. The Dow futures were mixed this morning, with the Dow gaining around 100 points. Groupon and Lyell Immunopharma were among the big stocks recording losses in today's pre- market trading.
Benzinga · 04/16 10:53
Reported Earlier, INOVIO Prices $36M Underwritten Offering Of 2,536,258 Common Stock At $7.693/Share
INOVIO Pharmaceuticals announced the pricing of an underwritten offering of 2,536,258 shares of its common stock. The company says the stock will be sold at a price of $7.693 per share in a public offering. The company is a maker of injectable pharmaceuticals.
Benzinga · 04/16 07:51
Inovio Announces Pricing Of About $36 Mln Offering Of Stock And Pre-Funded Warrants; Stock Drops
NASDAQ · 04/16 00:45
Inovio Shares Fall 23% After Underwritten Offering Prices
Biotechnology company Inovio priced an underwritten offering of stock and warrants. The company's stock was trading 23.6% lower in the after-hours market. Year to date, shares have risen by almost 80%. The company has a market cap of $257.78 million.
Dow Jones · 04/15 22:57
INOVIO ANNOUNCES PRICING OF APPROXIMATELY $36 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Reuters · 04/15 22:39
INOVIO PHARMACEUTICALS INC - PRICING OF AN UNDERWRITTEN OFFERING OF 2.5 MLN SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $7.693 PER SHARE
Reuters · 04/15 22:39
Weekly Report: what happened at INO last week (0408-0412)?
Weekly Report · 04/15 09:27
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga · 04/11 14:09
Weekly Report: what happened at INO last week (0401-0405)?
Weekly Report · 04/08 09:29
Geneos cancer vaccine shrinks liver tumors in small trial
Geneos cancer vaccine shrinks liver tumors in small trial. Nearly a third of patients with advanced liver cancer who received a personalized vaccine saw their tumors shrink. The result was roughly twice the response typically seen with the immunotherapy alone. The study suggests vaccines based on mutations only present in a patient's tumor may boost immune system.
Reuters · 04/07 20:30
Weekly Report: what happened at INO last week (0325-0329)?
Weekly Report · 04/01 09:28
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.